Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 84 of the 190 sources its claims cite were checked for support.

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges

Open access
Scala, Mauro, Fabbri, Chiara, Fusar-Poli, Paolo, Di Lorenzo, Giorgio, Ferrara, Maria, Amerio, Andrea, Fusar-Poli, Laura, Pichiecchio, Anna, Asteggiano, Carlo, Menchetti, Marco, De Ronchi, Diana, MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli, Giuseppe, Serretti, Alessandro · 2024 · CNS Spectrums

Abstract

The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-Assisted psychotherapy (PAP) and the methodological constraints of existing research. An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin's efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin's safety, long-term efficacy, and optimal dosage remain unclear due to previous trials' limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin's full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin's implementation in healthcare systems. © The Author(s), 2024. Published by Cambridge University Press.

Overview

CoChat Summary

## TL;DR

This critical review argues that psilocybin shows promising efficacy for depression and anxiety, but the evidence base is still limited by small, heterogeneous trials and major methodological gaps. The paper emphasizes that real-world use will require stronger randomized evidence, careful dosing and psychotherapy integration, and clear ethical/legal frameworks.

## Key findings

  • Across the reviewed literature, psilocybin showed the most robust evidence for major depressive disorder (MDD), anxiety/depressive symptoms associated with life-threatening cancer, and treatment-resistant depression (TRD); in a recent meta-analysis, psilocybin at 1 mg to 25 mg produced significant reductions in depressive symptoms in patients not taking other psychotropic medications.
  • In the 2021 RCT of 59 patients with MDD, there was no difference between psilocybin 25 mg and escitalopram by week 6 on QIDS-SR-16 (8.0 vs 6.0; p = 0.17).
  • In a 2023 randomized, double-blind, placebo-controlled trial of 52 patients with MDD, psilocybin 0.215 mg/kg produced greater symptom reduction than placebo by day 14 on MADRS (15.0 to 1.3; Cohen’s d = 0.97; p = 0.0011).
  • The paper reports a 2022 trial in 24 patients with MDD in which pretreatment psilocybin 20 and 30 mg/70 kg yielded an antidepressant response rate of 75% and remission of 58% by month 12; it also notes 33% of participants used other antidepressants during follow-up.

## Methods

  • This is a critical review, not a systematic review; the authors state it was intended to provide an expert clinical opinion on psilocybin’s evidence, practical implementation, and future directions.
  • They conducted an electronic literature search in PubMed/MEDLINE for English-language articles published from inception to December 2023, using psilocybin combined with terms related to depressive disorders, bipolar depression, anxiety disorders, OCD, PTSD, and SUD.
  • The review synthesized RCTs, non-randomized studies, open-label trials, pilot studies, secondary follow-up analyses, and meta-analyses, with attention to safety, dosing, PAP, ethics, and legal issues.

## Limitations

  • The paper states that the evidence comes from a mix of RCTs not always well-designed, non-randomized studies, open-label trials, and pilot studies, and that this prevents conclusive claims about antidepressant efficacy, especially long term.
  • It explicitly notes small sample sizes, lack of diversity, selection bias, inconsistent correction for multiple testing, lack of randomization in some studies, short follow-up, and frequent reliance on open-label, crossover, single-dose, and waiting-list designs.
  • The text also makes evident that conclusions are limited by the review’s non-systematic approach and by the fact that the authors rely heavily on previously published studies rather than new primary data.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s1092852924002268

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

49 Valid · 4 Not valid · 60 Not checked · 43 Own results and interpretations

95 more claims · 24 with their cited sources checked

Create a free account to see all 156 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 41
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 114 references

Research works printed but not linked: 2

  1. 10.1136/bmj.p1599;2023 · doi:10.1136/bmj.p1599;2023
  2. 107. Bender, L , Cobrinik, L , Faretra, G. Biological Treatment of Mental Illness: Proceedings of the II International Conference of the Manfred Sakel Foundation;1963.

Cited by

See all 13

Metadata

Authors
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., De Ronchi, D., MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli, G., & Serretti, A.
Affiliations
  • Research Institute Hospital 12 de Octubre (ES)
  • University of Bologna (IT)
  • University of Ferrara (IT)
  • University of Pavia (IT)
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
  • Radboud University Medical Center (NL)
  • Università degli Studi di Enna Kore (IT)
Corresponding author
Fanelli, Giuseppe
Venue
CNS Spectrums
Published
2024-12
Volume
29
Issue
6
Pages
570-584
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W4405207112
Cited by
13
References
114
Citations by year
2026: 5 · 2025: 8
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • CNS Spectrums (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System (University of Udine) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psilocybin, psychedelic-assisted psychotherapy, mood disorders, anxiety disorders, depression, obsessive-compulsive disorder, post-traumatic stress disorder, substance use disorders, dose optimization, translation to clinical practice, legal and ethical issues, cultural stigma
MeSH terms
Anxiety Disorders, Hallucinogens, Humans, Psilocybin, Psychotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. https://app.cochat.ai/papers/10.1017/s1092852924002268
The paper
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., De Ronchi, D., MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli, G., & Serretti, A. (2024). The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. CNS Spectrums. https://doi.org/10.1017/s1092852924002268

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.